文献速递临床试验与 GCP真实世界研究与卫生经济

比较LSVT LOUD与NHS言语治疗及对照在帕金森病中临床与成本效果的多中心随机对照试验:研究方案

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-05-27

BACKGROUND: Parkinson's disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social wit…

要点

  • PD COMM试验比较NHS言语治疗与LSVT LOUD对帕金森病言语或发声问题的疗效与成本效果。
  • 主要结局为随机后3个月嗓音障碍指数(VHI)总分。

核心结论

  • 该试验将检验言语治疗对帕金森病言语或发声问题有效的假设,并比较NHS言语治疗与LSVT LOUD的获益及成本效果。

研究设计与样本

  • 参与者按1:1:1随机分为无干预对照组、NHS言语治疗组或LSVT LOUD组,采用最小化程序含随机要素以确保分配隐藏。
  • NHS言语治疗组在随机后4周内开始治疗,LSVT LOUD组在随机后7周内开始治疗。
  • 评估在随机前及随机后3、6、12个月完成,试验于2015年12月启动,预计运行77个月,约42个英国中心招募。

主要发现

  • 原文未报告试验结果。

关键数值与推荐

  • 主要结局为3个月时嗓音障碍指数(VHI)总分。
  • 次要结局包括VHI子量表、帕金森病问卷-39、获得性言语障碍问卷、EuroQol-5D-5L、ICECAP-O、资源利用、不良事件及照护者生活质量。
  • NHS言语治疗通常为每周6至8次会话,LSVT LOUD为4周内16次个体治疗及家庭练习。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Parkinson's disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals' needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. METHODS/DESIGN: PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. PRIMARY OUTCOME: Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson's Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. DISCUSSION: The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. TRIAL REGISTRATION: International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sackley CM, Rick C, Au P, et al. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial. Trials. 2020. PMID: 32460885. doi:10.1186/s13063-020-04354-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。